Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer

Cancer

Volumn 121, Issue 15, 2015, Pages 2586-2593

  Galsky, Matthew D ^a   Pal, Sumanta K ^b   Chowdhury, Simon ^c   Harshman, Lauren C ^d   Crabb, Simon J ^e   Wong, Yu Ning ^f   Yu, Evan Y ^g   Powles, Thomas ^h   Moshier, Erin L ^a   Ladoire, Sylvain ⁱ   Hussain, Syed A ^j   Agarwal, Neeraj ^k   Vaishampayan, Ulka N ^l   Recine, Federica ^m   Berthold, Dominik ⁿ   Necchi, Andrea ^o   Theodore, Christine ^p   Milowsky, Matthew I ^q   Bellmunt, Joaquim ^d   Rosenberg, Jonathan E ^r  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^f FOX CHASE CANCER CENTER   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ Georges Francois Leclerc Center   (France)

^j UNIVERSITY OF LIVERPOOL   (United Kingdom)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^l KARMANOS CANCER INSTITUTE   (United States)

^m Department of Medical Oncology Samuel and Barbara Sternberg Cancer Research Foundation   (Italy)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p FOCH HOSPITAL   (France)

^q UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

bladder cancer; cisplatin; doxorubicin; gemcitabine plus cisplatin; methotrexate; muscle invasion; neoadjuvant; plus cisplatin; vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADJUVANT THERAPY; ADULT; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, TRANSITIONAL CELL; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); MUSCLE NEOPLASMS; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84937523625     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29387     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D., Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Bochner BH, Dalbagni G, Kattan MW, et al., Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006; 24: 3967-3972.
3. Galsky MD, Herr HW, Bajorin DE., The integration of chemotherapy and surgery for bladder cancer. J Natl Compr Canc Netw. 2005; 3: 45-51.
4. Grossman HB, Natale RB, Tangen CM, et al., Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
5. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171-2177.
6. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM., Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007; 178: 451-454.
7. von der Maase H, Hansen SW, Roberts JT, et al., Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
8. von der Maase H, Sengelov L, Roberts JT, et al., Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-4608.
9. Sonpavde G, Watson D, Tourtellott M, et al., Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer. 2012; 10: 1-5.
10. National Comprehensive Cancer Network (NCCN). NCCN Guidelines, version 2.2014. Bladder Cancer. Fort Washington, PA: NCCN; 2014. http://www.nccn.org/professionals/physician-gls/pdf/bladder.pdf. Accessed October 1, 2014.
11. Apolo AB, Kim JW, Bochner BH, et al., Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014; 32: 637-644.
12. Booth CM, Siemens DR, Peng Y, Tannock IF, Mackillop WJ., Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. Ann Oncol. 2014; 25: 1783-1788.
13. Sternberg CN, de Mulder P, Schornagel JH, et al., Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42: 50-54.
14. Pal SK, Ruel NH, Wilson TG, Yuh BE., Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2012; 10: 246-250.
15. Scosyrev E, Messing EM, van Wijngaarden E, et al., Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer. 2012; 118: 72-81.
16. Ault K., Multiple imputation for ordinal variables: a comparison of SUDAAN's PROC IMPUTE vs PROC MI. In: Southeast SAS Users Group (SESUG), ed. SESUG 2012: Proceedings of the Southeast SAS Users Group. Durham, NC: SESUG; 2012. Paper SD-12.
17. Herchenhorn D, Dienstmann R, Peixoto FA, et al., Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol. 2007; 33: 630-638; discussion 638.
18. Plimack ER, Hoffman-Censits JH, Kutikov A, et al., Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study [abstract]. J Clin Oncol. 2014; 32 (5S). Abstract 4513.
19. Dash A, Pettus JA 4th, Herr HW, et al., A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008; 113: 2471-2477.
20. Fairey AS, Daneshmand S, Quinn D, et al., Neoadjuvant chemotherapy with gemcitabine/cisplatin vs methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013; 31: 1737-1743.
21. Lee FC, Harris W, Cheng HH, et al., pathologic response rates of gemcitabine/cisplatin versus methotrexate/vinblastine/Adriamycin/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer. Adv Urol. 2013; 2013: 317190.
22. Weight CJ, Garcia JA, Hansel DE, et al., Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer. 2009; 115: 792-799.
23. Yuh BE, Ruel N, Wilson TG, Vogelzang N, Pal SK., Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol. 2013; 189: 1682-1686.
24. Yeshchina O, Badalato GM, Wosnitzer MS, et al., Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, Adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology. 2012; 79: 384-390.
25. Rosenbaum PR, Rubin DB., The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70: 41-55.
26. Austin PC., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011; 46: 399-424.
27. Sturmer T, Wyss R, Glynn RJ, Brookhart MA., Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014; 275: 570-580.
28. Dehejia RH, Wahba S., Causal effects in, nonexperimental studies: re-evaluating the evaluation of training programs. J Am Stat Assoc. 1999; 94: 1053-1062.
29. Heckman JJ, Pinto R., Econometric mediation analyses: identifying the sources of treatment effects from experimentally estimated production technologies with unmeasured and mismeasured inputs. Econ Rev. 2015; 34: 6-31.
30. Choueiri TK, Jacobus S, Bellmunt J, et al., Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014; 32: 1889-1894.
31. Plimack ER, Hoffman-Censits JH, Viterbo R, et al., Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014; 32: 1895-1901.
32. Blick C, Hall P, Pwint T, et al., Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer. 2012; 118: 3920-3927.
33. Sonpavde G, Goldman BH, Speights VO, et al., Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009; 115: 4104-4109.
34. Southwest Oncology Group, National Cancer Institute. A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer. http://www.clinicaltrials.gov/ct2/show/study/NCT02177695. Accessed January 23, 2015.